Technical Analysis for BYSI - BeyondSpring, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Below Lower BB | Weakness | -6.55% | |
| Down 3 Days in a Row | Weakness | -6.55% | |
| Gapped Down | Weakness | -6.55% |
| Alert | Time |
|---|---|
| Down 5% | about 12 hours ago |
| Down 1 ATR | about 12 hours ago |
| Down 3% | about 14 hours ago |
| Fell Below Previous Day's Low | about 14 hours ago |
| Down 2 % | about 14 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 04/18/2024
BeyondSpring, Inc. Description
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Cancer Treatment Chemotherapy Antineoplastic Drugs Small Cell Lung Cancer Cancer Therapies Organic Chemistry NSCLC Protein Kinase Advanced Non Small Cell Lung Cancer Buparlisib Docetaxel Neutropenia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.0 |
| 52 Week Low | 0.7777 |
| Average Volume | 23,645 |
| 200-Day Moving Average | 2.21 |
| 50-Day Moving Average | 2.21 |
| 20-Day Moving Average | 2.25 |
| 10-Day Moving Average | 2.14 |
| Average True Range | 0.14 |
| RSI (14) | 29.08 |
| ADX | 24.56 |
| +DI | 14.36 |
| -DI | 25.57 |
| Chandelier Exit (Long, 3 ATRs) | 2.10 |
| Chandelier Exit (Short, 3 ATRs) | 2.28 |
| Upper Bollinger Bands | 2.56 |
| Lower Bollinger Band | 1.94 |
| Percent B (%b) | -0.11 |
| BandWidth | 27.52 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.044 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.28 | ||||
| Resistance 3 (R3) | 2.31 | 2.22 | 2.21 | ||
| Resistance 2 (R2) | 2.22 | 2.11 | 2.20 | 2.18 | |
| Resistance 1 (R1) | 2.04 | 2.05 | 2.00 | 2.01 | 2.16 |
| Pivot Point | 1.95 | 1.95 | 1.92 | 1.93 | 1.95 |
| Support 1 (S1) | 1.77 | 1.84 | 1.73 | 1.74 | 1.58 |
| Support 2 (S2) | 1.68 | 1.78 | 1.66 | 1.56 | |
| Support 3 (S3) | 1.50 | 1.68 | 1.53 | ||
| Support 4 (S4) | 1.47 |
